Compare TransMedics Group Inc (TMDX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Wheaton Precious Metals Corp — how do they compare? TransMedics Group Inc trades at $86.4 (market cap $3.00B), while Wheaton Precious Metals Corp trades at $155.35 (market cap $71.45B). The key difference: Wheaton Precious Metals Corp is far larger — about 23.8× TransMedics Group Inc's market cap, and Wheaton Precious Metals Corp pays a 0.5% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WPM | |
|---|---|---|
Market Cap | $3.00B | $71.45B |
Sector | Technology | Basic Materials |
52-Week High | $150.42 | $165.72 |
52-Week Low | $61.99 | $94.37 |
Enterprise Value | $3.39B | $73.33B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Wheaton Precious Metals (WPM) trades at $155.11, up 0.08% with a bullish technical outlook and strong institutional support. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.19 beating expectations of $1.15. Revenue surged to $2.31 billion in 2025 with exceptional 64.66% net margins, while cash flow from operations reached $1.90 billion. Analysts maintain 80% buy ratings with a $161.75 consensus target, representing 4.3% upside potential.
WPM's streaming model provides leveraged exposure to precious metals without mining operational risks, supported by fully-funded growth pipeline targeting 50% production increase by 2030. Key risks include commodity price volatility and execution of the ambitious $5.1 billion 2026 investment plan. The stock offers growth potential but requires monitoring of gold/silver price trends and capital deployment efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
